Technical Analysis for JNCE - Jounce Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 4.99 5.72% 0.27
JNCE closed up 5.72 percent on Monday, March 30, 2020, on 82 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up
Historical JNCE trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
200 DMA Resistance Bearish 5.72%
Stochastic Reached Overbought Strength 5.72%
Wide Bands Range Expansion 5.72%
Overbought Stochastic Strength 5.72%
200 DMA Resistance Bearish -0.20%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.20%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company's lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells found in a range of solid tumors. It also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. Jounce Therapeutics, Inc. is based in Cambridge, United States.
Biotechnology Life Sciences Biology Natural Sciences Immunology Immunotherapy Solid Tumors Immune System Monoclonal Antibodies

Is JNCE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 10.0
52 Week Low 2.79
Average Volume 402,145
200-Day Moving Average 5.03
50-Day Moving Average 5.34
20-Day Moving Average 4.21
10-Day Moving Average 4.28
Average True Range 0.59
ADX 26.07
+DI 20.96
-DI 19.37
Chandelier Exit (Long, 3 ATRs ) 3.57
Chandelier Exit (Short, 3 ATRs ) 4.61
Upper Bollinger Band 5.53
Lower Bollinger Band 2.90
Percent B (%b) 0.79
BandWidth 62.53
MACD Line -0.17
MACD Signal Line -0.40
MACD Histogram 0.2328
Fundamentals Value
Market Cap 160.45 Million
Num Shares 32.2 Million
EPS 0.03
Price-to-Earnings (P/E) Ratio 166.33
Price-to-Sales 5.66
Price-to-Book 2.51
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.63
Resistance 3 (R3) 5.58 5.32 5.52
Resistance 2 (R2) 5.32 5.16 5.34 5.49
Resistance 1 (R1) 5.16 5.06 5.24 5.20 5.45
Pivot Point 4.89 4.89 4.94 4.92 4.89
Support 1 (S1) 4.73 4.73 4.81 4.78 4.53
Support 2 (S2) 4.47 4.63 4.49 4.49
Support 3 (S3) 4.30 4.47 4.46
Support 4 (S4) 4.35